Organoid Personalized Therapeutics and the P ancreatic A denocarcinoma S ignature S tratification for treatment (PASS) – 01 trial

Keywords: pancreatic cancer, patient-derived organoids, transcriptomic signatures, PASS-01 Background: Patients with advanced pancreatic ductal adenocarcinoma (PDAC) continue to have a dire prognosis and only a minority of patients is fit enough to receive second-line treatment. Secondary and explor...

Full description

Saved in:
Bibliographic Details
Published in:Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2020-12, Vol.20 (8), p.e16
Main Authors: Froeling, Fieke EM, Plenker, Dennis, Grainne O’Kane, Aguirre, Andrew J, Wolpin, Brian M, Laheru, Daniel A, Saif, M Wasif, Yu, Kenneth H, Fischer, Sandra, Gallinger, Steven, Knox, Jennifer J, Jaffee, Elizabeth M, Tuveson, David A
Format: Article
Language:English
Subjects:
Adenocarcinoma
Biomarkers
Cancer therapies
Chemotherapy
Medical prognosis
Metastasis
Organoids
Pancreatic cancer
Patients
Ribonucleic acid
RNA
Transcriptomics
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Keywords: pancreatic cancer, patient-derived organoids, transcriptomic signatures, PASS-01 Background: Patients with advanced pancreatic ductal adenocarcinoma (PDAC) continue to have a dire prognosis and only a minority of patients is fit enough to receive second-line treatment. Secondary and exploratory objectives include determine the objective response rate, duration of response and overall survival associated with mFFX or GA, whether the chemotherapy sensitivity signature predictions correlate with responders, if PDO transcriptomic profiles parallel those obtained from patient samples, whether GATA6 expression can serve as a biomarker of response [4], the use of serial cell free circulating tumor DNA and circulating tumour cell analysis to identify emerging or de novo resistance and evaluate biomarkers of immune-oncologic sensitivity. At progression, as per RECIST 1.1 criteria, chemotherapy sensitivity signatures (RNA) and/or PDO pharmacotyping and WGS data will be used where possible to guide second-line therapy in an effort to continually provide the most active therapeutic regimens to each patient.
ISSN:1424-3903
1424-3911
DOI:10.1016/j.pan.2020.10.008